1) RFA’s to break the cycle of inertia
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has an estimated prevalence of 0,2% [1] to 0,4% [2], meaning it is more common than multiple sclerosis, AIDS or systemic lupus erythematosus. Patients with ME/CFS have been found to be more functionally impaired than those with other disabling illnesses, including congestive heart failure and end-stage renal disease. [3] The economic impact of ME/CFS in the US is estimated to be 18-24 billion dollars a year. [4]
Based on the estimated disease burden, equitable research funding for ME/CFS by the National Institutes of Health (NIH) would amount to 188 dollars million per year. [5] This is more than fifteen times the amount the NIH currently spends. [6] An enormous disparity exists between the research funding that is required and what is currently being done.
One of the main reasons for this is a lack of grant applications. Researchers are hesitant to jeopardize their career by entering a field where funding is uncertain. Research proposals in the field of ME/CFS could also be scarce due to the fear of being rejected on irrational grounds. Even internationally respected scientists such as Ronald Davis [8] and Ian Lipkin [9] have been rejected or ignored when they applied for research into ME/CFS. ME/CFS is a relatively new disease that suffers from stigma and prejudices, even within the research community and medical profession.
The result is a cycle of inertia where researchers are unwilling to enter the field as long as it remains underdeveloped. We believe the most efficient method to break this cycle is by earmarking funds for ME/CFS. By issuing requests for applications (RFA’s) the NIH could attract new researchers to study ME/CFS. This would reduce the disparity between the societal burden of ME/CFS and the dire lack of funding devoted to this illness. The use of RFA’s has been successful in the past in ME/CFS [9] and the development of other fields [10].
We, therefore, recommend the NIH to increase the number of RFA’s to further research into ME/CFS.
References
[1] Reyes M, Nisenbaum R, Hoaglin DC, Unger ER, Emmons C, Randall B, et al. Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med. 2003 Jul 14;163(13):1530-6.
[2] Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, et al. A communitybased study of chronic fatigue syndrome. Arch Intern Med. 1999 Oct 11;159(18):2129-37.
[3] Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, D.C.: The National Academies Press, 2015.
[4] Jason LA, Benton MC, Valentine L, Johnson A, Torres-Harding S. The economic impact of ME/CFS: individual and societal costs. Dyn Med. 2008 Apr 8;7:6.
[5] Dimmock ME, Mirin AA, Jason LA. Estimating the disease burden of ME/CFS in the United States and its relation to research funding. J Med Therap, 2016;1(1):1-7.
[6] Spotila J. (2018, October 21). NIH Funding for ME Goes Down in 2018. occupyme.net. Available at:
https://occupyme.net/2018/10/21/nih-funding-for-me-goes-down-in-2018/
[7] MEAction. (2015, 20 August). Ron Davis on why his NIH proposal was rejected.
https://www.meaction.net/2015/08/20/ron-davis-nih-proposal/
[8] Interview with Dr. W. Ian Lipkin, ME/CFS Alert Episode 95. (December 2, 2017).
[9] Neuroimmune Mechanisms and Chronic Fatigue Syndrome. RFA-OD-06-002.
https://grants.nih.gov/grants/guide/rfa-files/rfa-od-06-002.html
[10] Limited Competition of the MAPP Research Network (U01). RFA-DK-13-507.
https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-13-507.html